Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
University of Zurich
University of Zurich
Arkansas Children's Hospital Research Institute
Children's Hospital Medical Center, Cincinnati
University of Rochester
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Stanford University
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire, Amiens
UNC Lineberger Comprehensive Cancer Center
Fondazione Italiana Linfomi - ETS
Stanford University
Associazione Qol-one
Ruijin Hospital
Assiut University
Assistance Publique - Hôpitaux de Paris
Fondazione Italiana Linfomi - ETS
Oncology Institute of Southern Switzerland
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Young Adult Survivors United
University of Rochester
Affiliated Hospital of Qinghai University
Second Affiliated Hospital, School of Medicine, Zhejiang University
IRCCS San Raffaele
Asan Medical Center
The First Affiliated Hospital of Xinxiang Medical College
Rigshospitalet, Denmark
Sunnybrook Health Sciences Centre
Institut Bergonié
Fondazione Italiana Linfomi - ETS
UNC Lineberger Comprehensive Cancer Center
Samsung Medical Center
National Taiwan University Hospital
Montreal Heart Institute
Memorial Sloan Kettering Cancer Center
Assistance Publique - Hôpitaux de Paris
Peking University First Hospital
Rigshospitalet, Denmark
Region Skane
Arbeitsgemeinschaft medikamentoese Tumortherapie
Nottingham University Hospitals NHS Trust
Ruijin Hospital
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Ann & Robert H Lurie Children's Hospital of Chicago
Centre Leon Berard
Fred Hutchinson Cancer Center